Precigen (NASDAQ:PGEN) Director Sells $15,750,177.30 in Stock

Precigen, Inc. (NASDAQ:PGEN) Director Randal Kirk sold 4,772,781 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the sale, the director owned 302,213 shares of the company’s stock, valued at approximately $997,302.90. This trade represents a 94.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Precigen Trading Up 1.1%

Shares of PGEN stock traded up $0.04 during trading hours on Thursday, reaching $3.97. The company’s stock had a trading volume of 827,221 shares, compared to its average volume of 4,665,688. The company has a current ratio of 3.09, a quick ratio of 2.83 and a debt-to-equity ratio of 4.46. Precigen, Inc. has a one year low of $1.11 and a one year high of $5.47. The stock has a market capitalization of $1.41 billion, a P/E ratio of -2.96 and a beta of 1.12. The firm’s fifty day simple moving average is $4.04 and its 200 day simple moving average is $3.97.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. The company had revenue of $4.57 million during the quarter, compared to the consensus estimate of $8.29 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%. Equities research analysts expect that Precigen, Inc. will post -0.32 EPS for the current year.

Hedge Funds Weigh In On Precigen

Large investors have recently made changes to their positions in the business. NBC Securities Inc. bought a new stake in shares of Precigen in the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd bought a new position in Precigen during the 3rd quarter valued at approximately $39,000. Russell Investments Group Ltd. purchased a new position in Precigen during the third quarter valued at $41,000. Mason Investment Advisory Services Inc. bought a new stake in Precigen in the fourth quarter worth $42,000. Finally, Abel Hall LLC bought a new stake in Precigen in the fourth quarter worth $44,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. HC Wainwright boosted their price target on shares of Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Wall Street Zen upgraded Precigen from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Citizens Jmp increased their target price on Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $9.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.